Ann Conkle
Mar 20, 2012

Clinical trial of stem cell therapy for stroke begun

SanBio Inc. today announced that the first 6 patients, of a total of 18, have been successfully administered SB623, a new allogeneic stem cell therapy product, in the first clinical trial testing the safety and efficacy of the therapy in patients suffering from chronic deficits resulting from stroke. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "This represents a major milestone in the human clinical testing of this important new approach for regenerative medicine," said Keita Mori, SanBio CEO.  "We are pleased to learn that the initial dose level was well tolerated."

Companies
1
Patents
1
0 Comments
Related Articles
Ann Conkle
Feb 28, 2012
New stroke-preventing device demonstrated
Researchers from Atritech, now part of Boston Scientific, have developed the WATCHMAN device, a small mesh umbrella that can be... Read More
Ann Conkle
Mar 14, 2012
Expensive procedure no more effective than medical therapy to prevent strokes
A catheter procedure that closes a hole in patients' hearts was no more effective than medical therapy in preventing recurrent... Read More
Elisabeth Manville
Mar 19, 2012
Research team uses stem cells to study gene function in neurological disorders
A research team from Kansas State University, led by professor Mark Weiss, has perfected a technique that uses stem cells... Read More